Tofacitinib in chronic pouchitis: A step towards addressing an unmet need.
作者信息
Ollech Jacob E
机构信息
Division of Gastroenterology, Faculty of Medicine, Rabin Medical Center, Tel-Aviv University, Tel Aviv, Israel.
出版信息
United European Gastroenterol J. 2025 May;13(4):501-502. doi: 10.1002/ueg2.12691. Epub 2024 Nov 7.
Abstract
摘要
相似文献
1
Tofacitinib in chronic pouchitis: A step towards addressing an unmet need.托法替布治疗慢性袋炎：朝着满足未满足需求迈进的一步。
United European Gastroenterol J. 2025 May;13(4):501-502. doi: 10.1002/ueg2.12691. Epub 2024 Nov 7.
2
A case of refractory chronic pouchitis successfully treated with tofacitinib.托法替尼成功治疗难治性慢性袋炎 1 例。
Clin J Gastroenterol. 2020 Aug;13(4):560-563. doi: 10.1007/s12328-020-01108-5. Epub 2020 Mar 4.
3
Tofacitinib for the treatment of chronic pouchitis: A pilot study.托法替布治疗慢性袋炎：一项初步研究。
United European Gastroenterol J. 2025 Mar;13(2):201-209. doi: 10.1002/ueg2.12683. Epub 2025 Feb 2.
4
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics.托法替布在对生物制剂多重难治的慢性袋炎患者中的有效性和安全性。
Dig Liver Dis. 2023 Aug;55(8):1158-1160. doi: 10.1016/j.dld.2023.04.028. Epub 2023 May 28.
5
Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States.托法替布治疗慢性炎症性袋状病变：来自美国两个三级炎症性肠病中心的病例系列
Inflamm Bowel Dis. 2023 Sep 1;29(9):1504-1507. doi: 10.1093/ibd/izad011.
6
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study.口服托法替布治疗慢性袋炎的有效性：一项前瞻性、开放标签的试点研究。
Inflamm Bowel Dis. 2024 Oct 3;30(10):1907-1910. doi: 10.1093/ibd/izad191.
7
Editorial: biologic therapy for chronic pouchitis - are we beginning to meet the unmet need?社论：慢性袋炎的生物治疗——我们是否开始满足未被满足的需求？
Aliment Pharmacol Ther. 2018 Mar;47(6):857-858. doi: 10.1111/apt.14542.
8
Broadening perspectives in the treatment of chronic pouchitis.拓宽慢性袋炎治疗的视野。
Rev Esp Enferm Dig. 2024 Dec;116(12):724-725. doi: 10.17235/reed.2024.10865/2024.
9
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand.小分子药物在溃疡性结肠炎回肠贮袋肛管吻合术后治疗炎症性袋状疾病方面是否有效？这就是我们目前的立场。
Biomolecules. 2024 Sep 17;14(9):1164. doi: 10.3390/biom14091164.
10
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.真实世界中在三级中心使用托法替布治疗炎症性肠病的经验。
Dig Dis Sci. 2019 Jul;64(7):1945-1951. doi: 10.1007/s10620-019-05492-y. Epub 2019 Feb 7.
本文引用的文献
1
Tofacitinib for the treatment of chronic pouchitis: A pilot study.托法替布治疗慢性袋炎：一项初步研究。
United European Gastroenterol J. 2025 Mar;13(2):201-209. doi: 10.1002/ueg2.12683. Epub 2025 Feb 2.
2
Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.维多珠单抗治疗慢性袋炎患者的黏膜愈合：EARNEST，一项随机、双盲、安慰剂对照试验。
Clin Gastroenterol Hepatol. 2025 Feb;23(2):321-330.e3. doi: 10.1016/j.cgh.2024.06.037. Epub 2024 Jul 16.
3
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics.托法替布在对生物制剂多重难治的慢性袋炎患者中的有效性和安全性。
Dig Liver Dis. 2023 Aug;55(8):1158-1160. doi: 10.1016/j.dld.2023.04.028. Epub 2023 May 28.
4
Vedolizumab for the Treatment of Chronic Pouchitis.维得利珠单抗治疗慢性袋炎。
N Engl J Med. 2023 Mar 30;388(13):1191-1200. doi: 10.1056/NEJMoa2208450.
5
Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States.托法替布治疗慢性炎症性袋状病变：来自美国两个三级炎症性肠病中心的病例系列
Inflamm Bowel Dis. 2023 Sep 1;29(9):1504-1507. doi: 10.1093/ibd/izad011.
6
Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial.粪便钙卫蛋白和生活质量问卷对抗生素治疗后储袋疾病活动度的变化有反应：一项前瞻性临床试验的结果
Am J Gastroenterol. 2023 Feb 1;118(2):367-370. doi: 10.14309/ajg.0000000000002038. Epub 2022 Sep 30.
7
Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series.托法替布治疗储袋相关疾病：病例系列
Inflamm Bowel Dis. 2022 Nov 2;28(11):1787-1789. doi: 10.1093/ibd/izac147.
8
Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease.粪便钙卫蛋白在 pouchitis 中增加，并随着内镜和组织学疾病的严重程度逐渐增加。
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1839-1846.e2. doi: 10.1016/j.cgh.2021.11.012. Epub 2021 Nov 16.
9
Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.慢性抗生素难治性 pouchitis 中生物治疗的结果：回顾性单中心经验。
United European Gastroenterol J. 2019 Nov;7(9):1215-1225. doi: 10.1177/2050640619871797. Epub 2019 Aug 20.
10
The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors.接受储袋手术的溃疡性结肠炎患者的预后由术前因素决定。
Aliment Pharmacol Ther. 2017 Sep;46(5):508-515. doi: 10.1111/apt.14205. Epub 2017 Jun 30.
Zotero 插件